argenx Announces Results of Annual General Meeting of Shareholders
argenx SE (Euronext & Nasdaq: ARGX) held its Annual General Meeting of shareholders on May 27, 2025, with 91.1% of the company's share capital represented. Most agenda items received majority approval, except for the remuneration policy (agenda item 5) which received 73.0% approval, falling short of the required 75% threshold.
Key approved resolutions included: the 2024 remuneration report (76.7% in favor), 2024 annual report and accounts (99.9% approval), re-appointment of Anthony Rosenberg as non-executive director (93.6% approval), and authorization for the Board to issue shares up to 10% of outstanding share capital (99.4% approval).
argenx SE (Euronext e Nasdaq: ARGX) ha tenuto l'Assemblea Generale Annuale degli azionisti il 27 maggio 2025, con il 91,1% del capitale sociale rappresentato. La maggior parte dei punti all'ordine del giorno ha ricevuto l'approvazione della maggioranza, ad eccezione della politica retributiva (punto 5 dell'ordine del giorno) che ha ottenuto un'approvazione del 73,0%, non raggiungendo la soglia richiesta del 75%.
Le risoluzioni chiave approvate includono: il rapporto retributivo 2024 (76,7% favorevoli), il bilancio e la relazione annuale 2024 (99,9% di approvazione), la riconferma di Anthony Rosenberg come amministratore non esecutivo (93,6% di approvazione) e l'autorizzazione al Consiglio di Amministrazione di emettere azioni fino al 10% del capitale sociale in circolazione (99,4% di approvazione).
argenx SE (Euronext y Nasdaq: ARGX) celebró su Junta General Anual de accionistas el 27 de mayo de 2025, con un 91,1% del capital social representado. La mayoría de los puntos del orden del día recibieron aprobación mayoritaria, excepto la política de remuneración (punto 5 del orden del día), que obtuvo un 73,0% de aprobación, quedando por debajo del umbral requerido del 75%.
Las resoluciones clave aprobadas incluyeron: el informe de remuneraciones 2024 (76,7% a favor), el informe y cuentas anuales 2024 (99,9% de aprobación), la reelección de Anthony Rosenberg como director no ejecutivo (93,6% de aprobación) y la autorización al Consejo para emitir acciones hasta un 10% del capital social en circulación (99,4% de aprobación).
argenx SE (유로넥스트 및 나스닥: ARGX)는 2025년 5월 27일 연례 주주총회를 개최했으며, 회사 주식 자본의 91.1%가 대표되었습니다. 대부분의 안건은 과반수 찬성을 받았으나, 보수 정책(안건 5)은 73.0% 찬성으로, 요구되는 75% 기준에 미치지 못했습니다.
주요 승인된 결의안에는 2024년 보수 보고서(76.7% 찬성), 2024년 연례 보고서 및 재무제표(99.9% 승인), 비상무 이사 Anthony Rosenberg 재선임(93.6% 승인), 그리고 이사회가 발행 주식의 최대 10%까지 신주를 발행할 수 있는 권한 부여(99.4% 승인)가 포함되었습니다.
argenx SE (Euronext et Nasdaq : ARGX) a tenu son Assemblée Générale Annuelle des actionnaires le 27 mai 2025, avec 91,1% du capital social représenté. La plupart des points à l'ordre du jour ont reçu une approbation majoritaire, à l'exception de la politique de rémunération (point 5 de l'ordre du jour) qui a obtenu 73,0% d'approbation, en dessous du seuil requis de 75%.
Les résolutions clés approuvées comprenaient : le rapport sur la rémunération 2024 (76,7% en faveur), le rapport annuel et les comptes 2024 (99,9% d'approbation), la réélection d'Anthony Rosenberg en tant qu'administrateur non exécutif (93,6% d'approbation) et l'autorisation donnée au Conseil d'émettre des actions jusqu'à 10% du capital social en circulation (99,4% d'approbation).
Die argenx SE (Euronext & Nasdaq: ARGX) hielt am 27. Mai 2025 ihre Jahreshauptversammlung der Aktionäre ab, bei der 91,1% des Aktienkapitals vertreten waren. Die meisten Tagesordnungspunkte wurden mehrheitlich genehmigt, mit Ausnahme der Vergütungspolitik (Tagesordnungspunkt 5), die mit 73,0% Zustimmung die erforderliche Schwelle von 75% nicht erreichte.
Wichtig genehmigte Beschlüsse waren unter anderem: der Vergütungsbericht 2024 (76,7% Zustimmung), der Jahresbericht und die Jahresabschlüsse 2024 (99,9% Zustimmung), die Wiederbestellung von Anthony Rosenberg als nicht geschäftsführendes Vorstandsmitglied (93,6% Zustimmung) sowie die Ermächtigung des Vorstands, Aktien bis zu 10% des ausstehenden Aktienkapitals auszugeben (99,4% Zustimmung).
- None.
- None.
May 28, 2025 – 10:01 PM CET
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held on May 27, 2025.
All items on the agenda received the required majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). This agenda item received a
As part of the approved resolutions:
- The Company’s 2024 remuneration report received a
76.7% majority in favor advisory vote; - The Company's annual report and annual accounts for the financial year ending December 31, 2024 were approved with a
99.9% majority; - Anthony Rosenberg has been re-appointed as non-executive director to the Board of Directors for a term of two years with a
93.6% majority; and - The Board of Directors was authorized to issue shares and grant rights to subscribe for shares in the share capital of the Company for up to
10% of the outstanding share capital at the date of the meeting and for a period of 18 months from the meeting and to limit or exclude statutory pre-emptive rights with a99.4% majority.
The voting result and all documents relating to the shareholders’ meeting will be available on the argenx
website at www.argenx.com/investors/shareholder-meetings.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
Bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
FAQ
What were the key results of ARGX's 2025 Annual General Meeting?
Why did ARGX's remuneration policy fail to pass at the 2025 AGM?
Who was re-appointed to ARGX's Board of Directors in the 2025 AGM?
What share issuance authority was granted to ARGX's Board in the 2025 AGM?
